Biologic therapy for psoriasis during the covid-19 outbreak is not a choice

Bardazzi, Federico; Loi, Camilla; Sacchelli, Lidia; Altobrando, Ambra Di

doi:10.1080/09546634.2020.1749545

Cited by 30 publications

(34 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, our observation strengthens the hypothesis that IL-23/IL-17 axis inhibition might not be detrimental in the setting of COVID-19 infection, even though it remains of upmost importance to collect more evidences and to gather as many cases as possible related to psoriasis patients in biological therapy who have contracted COVID-19, in order to better quantify the risk of infection under biologic therapy. 5 The patients in this manuscript have given written informed consent to publication of their case details.…”

Section: Editormentioning

confidence: 99%

“…Reports of chilblains-like lesions circulate on social medias and have appeared in the literature. 4,5 Google Trends (GT) provides data on the relative search volumes (RSV) of queries and topics over time and across geographical areas (https://trends.google.com/trends/). It allows seasonal and longterm assessment of trends in the public interest, including during COVID-19 outbreak.…”

Section: The Use Of Google Trends For Acral Symptoms During Covid-19 mentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor

Balestri

Rech

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Editormentioning

confidence: 99%

Section: The Use Of Google Trends For Acral Symptoms During Covid-19 mentioning

confidence: 99%

SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor

Balestri

Rech

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…[5][6] To date, there is neither an agreement nor a study sustaining the impact of continuing or stopping biologics in psoriatic patients during the COVID-19 pandemic. [7][8][9][10] The PSO-BIO-COVID is an observational, multicentric study, supported by the Italian Society of Dermatology (SIDeMaST), aimed at evaluate the impact of SARS-CoV-2 infection on the management of patients with psoriasis in Italy, during the first year of the pandemic.…”

Section: Dear Editormentioning

confidence: 99%

“…Talamonti, 1, † M. Galluzzo, 1, † A. Chiricozzi, 2,3, † P. Quaglino, 4 G. Fabbrocini, 5 P. Gisondi, 6 A.V. Marzano, 7,8 C. Potenza, 9 A. Conti, 10 A.…”

Section: Funding Sourcesunclassified

Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy

Talamonti¹,

Galluzzo²,

Chiricozzi³

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…8,9 To date, there is neither an agreement nor a study sustaining the impact of continuing or stopping biologics in psoriatic patients during the COVID-19 pandemic. [10][11][12][13][14][15][16] Furthermore, data on the epidemiology of COVID-19 disease in patients treated with biological drugs are very scarce. 8 A C…”

mentioning

confidence: 99%

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Talamonti

Galluzzo

Chiricozzi

et al. 2021

Expert Opinion on Biological Therapy

Self Cite

View full text Add to dashboard Cite

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

show abstract

Biologic therapy for psoriasis during the covid-19 outbreak is not a choice

Cited by 30 publications

References 12 publications

SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor

SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor

Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Contact Info

Product

Resources

About